Expand ACET Menu
ACET MENU

ACET Latest Press Releases

-- January 8, 2025 --

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones Business Wire 4:10 PM

-- December 31, 2024 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:48 PM

-- December 19, 2024 --

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Business Wire 7:00 AM

-- December 18, 2024 --

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer Business Wire 7:00 AM

-- November 29, 2024 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:44 PM

-- November 18, 2024 --

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Business Wire 4:00 PM
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases Business Wire 7:00 AM

-- November 16, 2024 --

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 Business Wire 9:00 AM

-- November 6, 2024 --

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates Business Wire 4:00 PM

-- November 5, 2024 --

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 Business Wire 7:00 AM

-- November 1, 2024 --

Adicet Bio to Participate in Upcoming Investor Conferences Business Wire 7:00 AM

-- October 31, 2024 --

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:31 PM

-- September 30, 2024 --

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:08 PM
Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference Business Wire 4:30 PM
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases Business Wire 7:00 AM

-- September 19, 2024 --

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue Business Wire 7:00 AM

-- August 30, 2024 --

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:44 PM

-- August 27, 2024 --

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference Business Wire 4:00 PM

-- August 19, 2024 --

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors Business Wire 7:00 AM